Methodological validation of Miro1 retention as a candidate Parkinson’s disease biomarker

Layla Drwesh; Giuseppe Arena; Daniel J. Merk; Daniele Ferrante; Vyron Gorgogietas; Thomas Gasser; Anne Grünewald; Patrick May; Kathrin Brockmann; Rejko Krüger; Richard Wüst; Christian Johannes Gloeckner; Julia C. Fitzgerald

doi:10.1038/s41531-025-01115-8

Methodological validation of Miro1 retention as a candidate Parkinson’s disease biomarker

Layla Drwesh
, Giuseppe Arena
, Daniel J. Merk
, Daniele Ferrante
, Vyron Gorgogietas
, Thomas Gasser
, Anne Grünewald
, Patrick May
, Kathrin Brockmann
, Rejko Krüger
, Richard Wüst
, Christian Johannes Gloeckner
, Julia C. Fitzgerald^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

4 Citations (Scopus)

Abstract

Mitochondrial markers help stratify Parkinson's disease (PD) patients. We use high-throughput blotting to quantify Miro1, Mfn2, and VDAC levels in fibroblasts, blood cells, and iPSC-derived neurons. Miro1 is specifically retained in PD cells but degraded in healthy ones after mitochondrial depolarization. We correlate Miro1 retention scores with pathogenic mutations, genetic background, age, and clinical data. This scalable assay and quantifiable score for mitochondrial-PD support biomarker development and pharmacological screening.

Original language	English
Article number	270
Journal	npj Parkinson's Disease
Volume	11
Issue number	1
DOIs	https://doi.org/10.1038/s41531-025-01115-8
Publication status	Published - 15 Sept 2025
Externally published	Yes

Access to Document

10.1038/s41531-025-01115-8

Cite this

@article{9ea3cf1a069046c1acf0a73c0c0c8d6c,

title = "Methodological validation of Miro1 retention as a candidate Parkinson{\textquoteright}s disease biomarker",

abstract = "Mitochondrial markers help stratify Parkinson's disease (PD) patients. We use high-throughput blotting to quantify Miro1, Mfn2, and VDAC levels in fibroblasts, blood cells, and iPSC-derived neurons. Miro1 is specifically retained in PD cells but degraded in healthy ones after mitochondrial depolarization. We correlate Miro1 retention scores with pathogenic mutations, genetic background, age, and clinical data. This scalable assay and quantifiable score for mitochondrial-PD support biomarker development and pharmacological screening.",

author = "Layla Drwesh and Giuseppe Arena and Merk, \{Daniel J.\} and Daniele Ferrante and Vyron Gorgogietas and Thomas Gasser and Anne Gr{\"u}newald and Patrick May and Kathrin Brockmann and Rejko Kr{\"u}ger and Richard W{\"u}st and Gloeckner, \{Christian Johannes\} and Fitzgerald, \{Julia C.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = sep,

day = "15",

doi = "10.1038/s41531-025-01115-8",

language = "English",

volume = "11",

journal = "npj Parkinson's Disease",

issn = "2373-8057",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - Methodological validation of Miro1 retention as a candidate Parkinson’s disease biomarker

AU - Drwesh, Layla

AU - Arena, Giuseppe

AU - Merk, Daniel J.

AU - Ferrante, Daniele

AU - Gorgogietas, Vyron

AU - Gasser, Thomas

AU - Grünewald, Anne

AU - May, Patrick

AU - Brockmann, Kathrin

AU - Krüger, Rejko

AU - Wüst, Richard

AU - Gloeckner, Christian Johannes

AU - Fitzgerald, Julia C.

PY - 2025/9/15

Y1 - 2025/9/15

N2 - Mitochondrial markers help stratify Parkinson's disease (PD) patients. We use high-throughput blotting to quantify Miro1, Mfn2, and VDAC levels in fibroblasts, blood cells, and iPSC-derived neurons. Miro1 is specifically retained in PD cells but degraded in healthy ones after mitochondrial depolarization. We correlate Miro1 retention scores with pathogenic mutations, genetic background, age, and clinical data. This scalable assay and quantifiable score for mitochondrial-PD support biomarker development and pharmacological screening.

AB - Mitochondrial markers help stratify Parkinson's disease (PD) patients. We use high-throughput blotting to quantify Miro1, Mfn2, and VDAC levels in fibroblasts, blood cells, and iPSC-derived neurons. Miro1 is specifically retained in PD cells but degraded in healthy ones after mitochondrial depolarization. We correlate Miro1 retention scores with pathogenic mutations, genetic background, age, and clinical data. This scalable assay and quantifiable score for mitochondrial-PD support biomarker development and pharmacological screening.

UR - https://www.scopus.com/pages/publications/105016330507

U2 - 10.1038/s41531-025-01115-8

DO - 10.1038/s41531-025-01115-8

M3 - Article

C2 - 40954161

AN - SCOPUS:105016330507

SN - 2373-8057

VL - 11

JO - npj Parkinson's Disease

JF - npj Parkinson's Disease

IS - 1

M1 - 270

ER -

Methodological validation of Miro1 retention as a candidate Parkinson’s disease biomarker

Abstract

Access to Document

Other files and links

Fingerprint

Cite this